Clinical trials: HIV Lipodystrophy
HIV Infections, Fatigue
Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS
This study will examine abnormalities in mitochondria (energy-producing machinery of cells) and in genes related to mitochondria in the blood cells, muscle, and fat of HIV-positive patients who are taking nucleoside reverse…
- Conditions
- HIV Infections, Fatigue, HIV Positive, AIDS
- Trial name
- NCT00106795
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
The purpose of this study is to determine what combinations of anti-HIV drugs work best in patients treated over several years. The study will also assess the occurrence of side effects and opportunistic infections in patients…
- Trial name
- NCT00001137
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 5,982 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections, HIV-Associated Lipodystrophy Syndrome
Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
The aim of this randomized study is to compare the occurrence of lipoatrophy in HIV-1 infected, naive patients receiving either a nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapy with…
- Trial name
- NCT00122668
- Testing
- non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitor
- Where
- France
- Volunteers
- 112 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections, Cardiovascular Disease
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
We hypothesize that the hearts of HIV+ people with The Metabolic Syndrome use and oxidize fats and sugars inappropriately, and that this may impair the heart's ability to pump blood.
- Conditions
- HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy
- Trial name
- WU197 (NCT00656851)
- Testing
- Pioglitazone, Exercise Training
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV-Associated Lipodystrophy Syndrome
Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
Aim: To assess the safety on the progression of HIV infection and the efficacy on the evolution of metabolic parameters and body fat of either viral load- or CD4 cell-driven strategies of intermittent treatment in chronically…
- Trial name
- NCT00646984
- Testing
- Standard continuous antiretroviral therapy, CD-4 guided therapy interruption, Viral load driven treatment interruption
- Where
- Spain
- Volunteers
- 147 people
- Sponsor
- Hospital Clinic of Barcelona
HIV Infections, Lipodystrophy
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
The purpose of this study is to learn whether changing from a type of anti-HIV drug called a protease inhibitor (PI) to another type of anti-HIV drug will help to lower the amount of fats or sugars in the blood.
- Trial name
- NCT00021463
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz
- Where
- 11 sites in United States
- Volunteers
- 342 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-Associated Lipodystrophy, HIV Infections
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy
This is a multi-centre, open-label, 96 week study to evaluate the safety, tolerability and extent and duration of improvement in HIV-1 infected subjects with antiretroviral induced facial lipoatrophy, randomised in a 1:1 ratio to…
- Trial name
- NCT00126308
- Testing
- poly-L-lactic acid
- Where
- 18 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Kirby Institute
HIV Infection
A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine
The purpose of this study is to compare the body fat distribution in Human Immunodeficiency Virus-1 (HIV-1) infected patients receiving, since the beginning and for at least two years, an antiretroviral therapy based on efavirenz…
- Trial name
- LYNX (NCT01159743)
- Where
- 26 sites in Spain
- Volunteers
- 346 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections, Type 2 Diabetes
Exercise and Pioglitazone for HIV-Metabolic Syndromes
The purpose is to examine the safety and efficacy of 16wks of pioglitazone (Actos; 30mg/d) with and without aerobic and strength exercise training for reducing glucose intolerance and central adiposity in HIV-infected people.
- Conditions
- HIV Infections, Type 2 Diabetes, Obesity, HIV
- Trial name
- NCT00639457
- Testing
- Pioglitazone, Exercise training
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infection
SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function
HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside analogues from stavudine (d4T) to tenofovir…
- Trial name
- NCT00225082
- Testing
- Nucleoside analogue switch
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
HIV Infection, Mitochondrial Dysfunction
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
The purposes of this study are to evaluate if switching an antiretroviral medication from efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change: 1.
- Trial name
- NCT01194856
- Testing
- Atazanavir/ritonavir, Efavirenz
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Cleveland Clinic
Cardiovascular Diseases, Heart Diseases
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
This study will evaluate the efficacy of diet and exercise (DE), with and without niacin and fenofibrate, in reducing the cardiovascular risk of patients with HIV lipodystrophy or dyslipidemia.
- Conditions
- Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia
- Trial name
- HeartPositive (NCT00246376)
- Testing
- Diet, Exercise, Niacin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Baylor College of Medicine
HIV-1-infection, Antiviral Drug Adverse Reaction
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued treatment with a non- dolutegravir…
- Conditions
- HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities
- Trial name
- NCT04340388
- Testing
- Dolutegravir 50 MG, Antiretroviral/Anti HIV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Augusta University
HIV Infections
BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes
The purpose of this study is to assess differences in changes in plasma lipids between patients on saquinavir/ritonavir or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine as a first-line…
- Trial name
- NCT00389402
- Testing
- saquinavir/ritonavir, atazanavir/ritonavir
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- International Antiviral Therapy Evaluation Center
HIV Infections, Lipodystrophy
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
SHARE: Simple HAART with Abacavir, Reyataz, and Epivir
- Trial name
- NCT00426296
- Testing
- atazanavir (Reyataz), ritonavir (Norvir)
- Where
- United States
- Sponsor
- Clinical Alliance for Research & Education - Infectious Diseases, LLC.
HIV-Associated Lipodystrophy Syndrome
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including…
- Trial name
- NCT00135460
- Testing
- nucleoside analogue sparing HAART regimen
- Where
- 5 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Danish HIV Research Group
Insulin Resistance, Cardiovascular Diseases
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
The purpose of this study is to test whether chronic administration of the drug acipimox will improve hyperlipidemia and insulin sensitivity among HIV infected patients experiencing highly active antiretroviral therapy (HAART)…
- Conditions
- Insulin Resistance, Cardiovascular Diseases, Heart Diseases, HIV Infections
- Trial name
- NCT00246402
- Testing
- Acipimox
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HIV Infections, Lipodystrophy
Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids
The purpose of this study is to compare the safety and effectiveness of fenofibrate and pravastatin in treating HIV-positive patients who have abnormal levels of fat (lipids) in the blood.
- Trial name
- NCT00006412
- Testing
- Pravastatin sodium, Fenofibrate
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 630 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Lipodystrophy
Growth Hormone Dynamics and Cardiac Steatosis in HIV
Cardiac steatosis is increased among individuals with HIV, and may predispose to cardiac mechanical dysfunction and subsequent heart failure. The pathogenesis and treatment of cardiac steatosis is not well understood.
- Conditions
- Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
- Trial name
- NCT03826160
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
HIV Infection, Antiretroviral Side Effects
Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy
Combined antiretroviral therapy (cART) is associated with facial lipoatrophy, which is potentially stigmatizing for HIV-positive patients.
- Conditions
- HIV Infection, Antiretroviral Side Effects, Lipodystrophy Syndrome Related to HIV Infection
- Trial name
- LIPOPHILL (NCT01077765)
- Testing
- Eutrophill
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris